한글목차

유럽의 고활성 API 시장 규모는 2023년 59억 8,000만 달러에서 예측 기간 동안 CAGR 10.57%로 추이하고, 2033년에는 163억 3,000만 달러에 달할 것으로 예측되고 있습니다.

고활성 API 시장의 확대를 뒷받침하는 주요 요인은 암 이환율 증가와 API의 치료 용도의 확산입니다.

유럽의 고활성 API 시장은 암 이환율이 증가하고 다양한 치료 영역에서 HPAPI의 응용이 확대됨에 따라 현저한 성장을 이루고 있습니다. 이 지역의 견고한 제약 산업은 첨단 R&D 시설과 엄격한 규제 프레임워크에 힘입어 시장 개발을 촉진하고 있습니다. 유럽의 주요 기업은 수요 증가에 대응하기 위해 제조 능력과 공동 제휴에 많은 투자를 하고 있습니다. 또한 혁신적인 기술과 공정을 채택하여 고품질의 안전한 HPAPI 생산을 보장합니다. 또한 고활성 화합물의 취급에 익숙하고 안전성과 환경 규제 준수를 확보하고 제약 기업의 운영 비용을 절감하는 전문적인 제조 위탁 기관(CMO)에 대한 아웃소싱 경향이 강해지고 있음 시장을 밀어주고 있습니다.

본 보고서에서는 유럽의 고활성 API 시장을 조사했으며, 업계 동향, 기술·특허 동향, 법규제 환경, 시장 성장 촉진요인 및 억제요인, 시장 규모 추이와 예측, 주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.

목차

주요 요약

제1장 시장

• 동향 : 현재 및 미래의 영향 평가
  • 트렌드 1: 고효능 API의 봉쇄 기술의 진보
  • 트렌드 2: 고효능 API 제조 단위에 대한 투자 증가
  • 트렌드 3: 제약회사에 의한 고효능 API 생산의 CDMO에 아웃소싱
• 공급망/가치 개요
  • 공급망과 공급망의 위험
  • 밸류체인 분석
• 가격 분석
• 특허출원 동향(연도 및 국가별)
• 규제 상황
• 주요 세계적 사건의 영향 분석 : COVID-19
• 시장 역학:개요
  • 시장 성장 촉진요인
  • 시장 기회
  • 시장 성장 억제요인

제2장 지역

• 지역별 개요
• 유럽
  • 지역 개요
  • 시장성장추진인자
  • 시장의 과제
  • 프랑스
  • 독일
  • 영국
  • 스페인
  • 이탈리아
  • 기타

제3장 시장 : 경쟁 벤치마킹·기업 프로파일

• 다음 프론티어
• 지리적 평가
  • Almac Group
  • Axplora Group GmbH
  • BASF SE
  • CordenPharma International
  • Helsinn Healthcare SA.
  • ICROM
  • Lonza
  • Merck KGaA
  • Sterling Pharma SolutionsAlmac Group

제4장 조사 방법

영문목차

Introduction to Europe Highly Potent API Market

The Europe highly potent API market is projected to reach $16.33 billion by 2033 from $5.98 billion in 2023, growing at a CAGR of 10.57% during the forecast period 2023-2033. The primary factors propelling the expansion of the highly potent API market are the rising incidence of cancer, which boosts the demand for highly potent APIs, and the broadening range of therapeutic applications for these APIs.

Market Introduction

The Europe Highly Potent API market is experiencing significant growth, driven by increasing cancer prevalence and the expanding application of HPAPIs in various therapeutic areas. The region's robust pharmaceutical industry, supported by advanced R&D facilities and stringent regulatory frameworks, enhances market development. Key players in Europe are investing heavily in manufacturing capabilities and collaborative partnerships to meet the rising demand. Additionally, the adoption of innovative technologies and processes ensures the production of high-quality, safe HPAPIs. The market is further fueled by the growing outsourcing trend to specialized contract manufacturing organizations (CMOs) with expertise in handling highly potent compounds, ensuring compliance with safety and environmental regulations, and reducing operational costs for pharmaceutical companies.

Market Segmentation:

Segmentation 1: by Country

• U.K.
• Germany
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Competitive Strategy: The highly potent API market has numerous established players with product and service portfolios. Key players in the Europe highly potent API market analysed and profiled in the study involve established players offering products and services of highly potent API.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, type portfolio, and market penetration.

Some prominent names in the market include:

• Almac Group
• Axplora Group GmbH
• BASF Pharma Solutions
• CordenPharma International
• Helsinn Healthcare SA.
• ICROM
• Lonza
• Merck KGaA
• Sterling Pharma Solutions

Table of Contents

Executive Summary

Scope and Definition

1 Markets

• 1.1 Trends: Current and Future Impact Assessment
  • 1.1.1 Trend 1: Advancements in Containment Technologies for Highly Potent APIs
  • 1.1.2 Trend 2: Increasing Investment for Highly Potent API Manufacturing Units
  • 1.1.3 Trend 3: Pharmaceutical Companies Outsourcing Highly Potent APIs Production to CDMOs
• 1.2 Supply Chain /Value Overview
  • 1.2.1 Supply Chain and Risks within the Supply Chain
  • 1.2.2 Value Chain Analysis
• 1.3 Pricing Analysis
• 1.4 Patent Filing Trend (by Year, Country)
• 1.5 Regulatory Landscape
• 1.6 Impact Analysis for Key Global Events - COVID-19
• 1.7 Market Dynamics: Overview
  • 1.7.1 Market Drivers
    • 1.7.1.1 Increasing Incidence of Cancer Leading to Demand in the Adoption of Highly Potent APIs
    • 1.7.1.2 Advancements in Drug Delivery Technologies
    • 1.7.1.3 Expanding Therapeutic Applications of Highly Potent API
  • 1.7.2 Market Opportunities
    • 1.7.2.1 Growing Emphasis on Personalized Medicine
    • 1.7.2.2 Increasing Opportunities for Pharma Companies in Developing Markets
  • 1.7.3 Market Restraints
    • 1.7.3.1 Regulatory Complexity for Highly Potent APIs' Manufacturing
    • 1.7.3.2 High Development and Production Costs

2 Regions

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 France
  • 2.2.5 Germany
  • 2.2.6 U.K.
  • 2.2.7 Spain
  • 2.2.8 Italy
  • 2.2.9 Rest-of-Europe

3 Markets -Competitive Benchmarking & Company Profiles

• 3.1 Next Frontiers
• 3.2 Geographic Assessment
  • 3.2.1 Almac Group
    • 3.2.1.1 Overview
    • 3.2.1.2 Key Developments
    • 3.2.1.3 Top Products/Product/Service Portfolio
    • 3.2.1.4 Top Competitors
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Axplora Group GmbH
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products/Product/Service Portfolio
    • 3.2.2.3 Key Developments
    • 3.2.2.4 Top Competitors
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 BASF SE
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products/Product/Service Portfolio
    • 3.2.3.3 Key Developments
    • 3.2.3.4 Top Competitors
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 CordenPharma International
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products/Product/Service Portfolio
    • 3.2.4.3 Key Developments
    • 3.2.4.4 Top Competitors
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View
  • 3.2.5 Helsinn Healthcare SA.
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products/Product/Service Portfolio
    • 3.2.5.3 Key Developments
    • 3.2.5.4 Top Competitors
    • 3.2.5.5 Key Personnel
    • 3.2.5.6 Analyst View
  • 3.2.6 ICROM
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products/Product/Service Portfolio
    • 3.2.6.3 Top Competitors
    • 3.2.6.4 Key Personnel
    • 3.2.6.5 Analyst View
  • 3.2.7 Lonza
    • 3.2.7.1 Overview
    • 3.2.7.2 Top Products/Product/Service Portfolio
    • 3.2.7.3 Key Developments
    • 3.2.7.4 Top Competitors
    • 3.2.7.5 Key Personnel
    • 3.2.7.6 Analyst View
  • 3.2.8 Merck KGaA
    • 3.2.8.1 Overview
    • 3.2.8.2 Top Products/Product/Service Portfolio
    • 3.2.8.3 Key Developments
    • 3.2.8.4 Top Competitors
    • 3.2.8.5 Key Personnel
    • 3.2.8.6 Analyst View
  • 3.2.9 Sterling Pharma Solutions
    • 3.2.9.1 Overview
    • 3.2.9.2 Top Products/Product/Service Portfolio
    • 3.2.9.3 Key Developments
    • 3.2.9.4 Top Competitors
    • 3.2.9.5 Key Personnel
    • 3.2.9.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast